Evidence map›Paper›PMID 34631983›Full record

ArticleVirusdisease2021

The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting.

Gina Gamal Naguib, Tari George Michael, Yehia Elshazly, Maha Magdy Wahdan, Aya Mostafa, Ossama Ashraf Ahmed, Hany Dabbous, Heba Ismail Saad Aly, Mohamed Kamal Shaker, Hosam Samir Elbaz and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virusdisease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Gina Gamal NaguibDepartment of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Tari George MichaelDepartment of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Yehia ElshazlyDepartment of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Maha Magdy WahdanDepartment of Community, Environmental, and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Aya MostafaDepartment of Community, Environmental, and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Ossama Ashraf AhmedDepartment of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Hany DabbousDepartment of Tropical Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Heba Ismail Saad AlyDepartment of Tropical Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Mohamed Kamal ShakerDepartment of Tropical Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Hosam Samir ElbazDepartment of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Magdy El-SerafyDepartment of Tropical Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt.
Wahid DossDepartment of Tropical Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt.
Sherief Abd-ElsalamDepartment of Tropical Medicine and Infectious Diseases, Tanta University, Tanta, 35127 Egypt.ORCID 0000-0003-4366-2218
Manal Hamdy El-SayedDepartment of Pediatrics and Clinical Research Center, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Ain Shams University · EGCairo University · EGTanta University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to compare efficacy and safety of different combination regimens in re-treatment of HCV in the setting of inaccessibility of resistance testing. This real-life prospective study included 86 chronic HCV infected patients who experienced failure of treatment treated at Faculty of Medicine Ain shams Research Institute (MASRI) since 2018. 64% of the patients were males, with median age 50.2 years. They were re-treated using 1 of 3 proposed regimens of DAA combinations. One group received PAR/OMB/SOF/RBV for 12 weeks, another group received SOF/DAC/SIM/RBV for 12 weeks and a third received SOF/DAC/RBV for 24 weeks. Response to different regimens was assessed by comparing sustained virologic response (SVR) of each. Monitoring the occurrence of adverse events was performed. SVR was achieved in all but 3 patients (96.5% SVR), one in the SOF/DAC/SIM/RBV group and two in the SOF/DAC/RBV group. The group receiving RBV had more anaemia and hyperbilirubinemia. The first treatment regimen used was a significant predictor to SVR achievement. This study presents alternative treatment regimens for re-treatment of HCV patients in areas with limited resources in the case of non-availability of other regimens as velpatasvir, voxilaprevir, grazoprevir, elbasvir.

Indexed as

CirrhosisHCVRelapsersResistanceSofosbuvirViral hepatitis

Identifiers

PMID34631983
PMCPMC8473466
OpenAlexW3184360848

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.